Search hospitals > Illinois > Princeton
Illinois CancerCare-Princeton
Claim this profilePrinceton, Illinois 61356
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
377 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Princeton is a medical facility located in Princeton, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Princeton is involved with conducting 377 clinical trials across 475 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Bryan A. FallerCrossroads Cancer Center2 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
223 reported clinical trials
289 drugs studied
James L. WadeDecatur Memorial Hospital3 years of reported clinical research
Studies Recurrence
Studies Breast Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at Illinois CancerCare-Princeton
Breast Cancer
Prostate Cancer
Cancer
Lung Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Esophageal Adenocarcinoma
Bladder Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Princeton?
Illinois CancerCare-Princeton is a medical facility located in Princeton, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Princeton is involved with conducting 377 clinical trials across 475 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Princeton located?
Illinois CancerCare, Princeton Location:
- Address: 530 Park Ave E, Princeton, IL 61356
- Location: Approximately 1.5 miles east of downtown Princeton, accessible via E Peru St.
Who should I call to ask about financial aid or insurance network?
**Illinois CancerCare-Princeton Financial Assistance:**
- For financial assistance, including support for transportation, home care, child care, and lodging, contact the CancerCare Hopeline at **800-813-4673**.
- For insurance-related inquiries, reach out to the Business Office at **(309) 243-3500** or toll-free at **(866) 662-6564**.
- For billing and insurance questions related to Princeton Health System, contact OSF HealthCare at **(800) 421-5700**.
What insurance does Illinois CancerCare-Princeton accept?
Illinois CancerCare-Princeton accepts a wide range of insurance plans, including but not limited to Medicare, Aetna (HMO, PPO, POS), BCBS of Illinois (PPO, POS, EPO, Classic Blue HMO, HMOI, Blue Advantage HMO), Beech Street PPO, Cigna/Great West Healthcare (HMO, PPO, POS, Open Access), and United Health Care. Other accepted insurances include Coventry/First Health/Personal Care, Humana (HMO, PPO, Choice POS, Choice Care Network), and Multiplan. It's important to confirm physician participation in your plan and understand any pre-certification requirements.
What awards or recognition has Illinois CancerCare-Princeton received?
Illinois CancerCare-Princeton, located in Princeton, Illinois, is distinguished by the Quality Oncology Practice Initiative (QOPI®) Certification Program for adhering to the highest national standards for cancer care quality. The hospital is also celebrated by the Alliance for Clinical Trials in Oncology for being among the top enrollers in clinical research nationwide, underscoring its dedication to pioneering new cancer treatments through clinical trials.